ADMA/SDMA in elderly subjects with asymptomatic carotid atherosclerosis: values and site-specific association
- PMID: 24739810
- PMCID: PMC4013635
- DOI: 10.3390/ijms15046391
ADMA/SDMA in elderly subjects with asymptomatic carotid atherosclerosis: values and site-specific association
Abstract
Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOS) inhibitor known as a mediator of endothelial dysfunction and atherosclerosis. Circulating ADMA levels are correlated with cardiovascular risk factors such as hypercholesterolemia, arterial hypertension, diabetes mellitus, hyperhomocysteinemia, age and smoking. We assessed the relationship between ADMA values and site-specific association of asymptomatic carotid atherosclerosis (intima-media thickness (CIMT) and plaque) in elderly subjects. One hundred and eighty subjects underwent a complete history and physical examination, determination of serum chemistries and ADMA levels, and carotid ultrasound investigation (CUI). All subjects had no acute or chronic symptoms of carotid atherosclerosis. Statistical analyses showed that high plasma levels of ADMA/SDMA were positively correlated to carotid atherosclerosis (CIMT and plaque) (p<0.001), with significant site-specific association. Total cholesterol, low density lipoprotein cholesterol, triglycerides and C-reactive protein plasma concentrations were significantly associated with asymptomatic carotid atherosclerosis (p<0.001). High serum concentrations of ADMA and SDMA were associated with carotid atherosclerotic lesions as measured by CIMT ad plaque and may represent a new marker of asymptomatic carotid atherosclerosis in elderly subjects.
Similar articles
-
Relationship between asymmetric dimethylarginine and asymptomatic carotid atherosclerosis.J Biol Regul Homeost Agents. 2010 Jul-Sep;24(3):351-8. J Biol Regul Homeost Agents. 2010. PMID: 20846483
-
Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort.Stroke. 2009 Aug;40(8):2715-9. doi: 10.1161/STROKEAHA.109.552539. Epub 2009 Jun 4. Stroke. 2009. PMID: 19498184 Free PMC article.
-
Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Oct;31(5):621-8. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006. PMID: 17062918
-
Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.Pharmacol Rep. 2006 Mar-Apr;58(2):159-78. Pharmacol Rep. 2006. PMID: 16702618 Review.
-
Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases.Clin Chim Acta. 2003 Oct;336(1-2):1-12. doi: 10.1016/s0009-8981(03)00338-3. Clin Chim Acta. 2003. PMID: 14500028 Review.
Cited by
-
The issue of plasma asymmetric dimethylarginine reference range - A systematic review and meta-analysis.PLoS One. 2017 May 11;12(5):e0177493. doi: 10.1371/journal.pone.0177493. eCollection 2017. PLoS One. 2017. PMID: 28494019 Free PMC article.
-
Admission levels of asymmetric and symmetric dimethylarginine predict long-term outcome in patients with community-acquired pneumonia.Respir Res. 2017 Jan 23;18(1):25. doi: 10.1186/s12931-017-0502-4. Respir Res. 2017. PMID: 28114935 Free PMC article.
-
Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications.Int J Mol Sci. 2020 Mar 5;21(5):1798. doi: 10.3390/ijms21051798. Int J Mol Sci. 2020. PMID: 32150996 Free PMC article. Review.
-
Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control.Cardiovasc Diabetol. 2014 Dec 3;13:156. doi: 10.1186/s12933-014-0156-1. Cardiovasc Diabetol. 2014. PMID: 25467091 Free PMC article.
-
SDMA as a marker and mediator in cerebrovascular disease.Clin Sci (Lond). 2024 Oct 16;138(20):1305-1323. doi: 10.1042/CS20241021. Clin Sci (Lond). 2024. PMID: 39391895 Free PMC article. Review.
References
-
- Böger R.H. Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann. Med. 2006;38:126–136. - PubMed
-
- Zoccali C. Traditional and emerging cardiovascular and renal risk factors: An epidemiological perspective. Kidney Int. 2006;70:26–33. - PubMed
-
- Krempl T.K., Kähler J., Maas R., Silberhorn L., Meinertz T., Böger R.H. Elevation of asymmetric dimethylarginine (ADMA) in patients with unstable angina and recurrent cardiovascular events. Eur. Heart J. 2005;26:1846–1851. - PubMed
-
- Lu T.M., Ding Y.A., Lin S.J., Lee W.S., Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur. Heart J. 2003;24:1912–1919. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials